| Name | Title | Contact Details |
|---|---|---|
Edward Berg |
Vice President and Deputy General Counsel | Profile |
Edward Berg |
Vice President and Deputy General Counsel | Profile |
AgriMetis discovers, develops, and delivers innovative crop protection products. Our scientific approach is multidisciplinary and integrated which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others. The AgriMetis platform delivers rapid, efficient, and optimal solutions to challenges in crop protection by bringing innovative products and their production processes to the market faster for the $56 billion agricultural chemical industry.
Accurate. Accessible. Actionable. Simplifying PCR, transforming healthcare.
Learn why 2,000+ healthcare organizations and employers depend on our experts to improve patient outcomes with advanced diagnostics.
CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.